Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1927 results
August 2019
-
Story Patient Perspectives
Living with HFpEF – a patient’s story
Cynthia lives with Heart Failure with preserved Ejection Fraction, a complex and challenging condition.
-
Ad hoc release
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio®* (teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary… -
Featured News
Blood Cancer Awareness Month - Cutting Edge Innovation in Hematology
-
Featured News
Impact Measurement and Valuation
Novartis joins seven global companies to found the Value Balancing Alliance
-
Press release
Novartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019
PARAGON-HF trial will provide Entresto® (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF)[1] New PROVE-HF and EVALUATE-HF studies will… -
Press release
AveXis Statement on Changes to Senior Leadership Team
AveXis announces Page Bouchard, DVM has been appointed Senior Vice President of Research and Chief Scientific Officer, effective August 5, 2019. Dr. Bouchard is a 27-year industry veteran with… -
Press release
Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case
Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit Ruling prevents launch of important, affordable treatment option for US patients affected by chronic… -
Story Discovery
Using Super-Resolution Microscopy To See Neurodegeneration
Novartis data scientists are using super-resolution microscopy to see neurodegeneration the moment it starts.
-
Press release
Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
Basel, August 6, 2019 – Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma® (onasemnogene abeparvovec-xioi). First and… -
Story Discovery
Keeping the heart of patients at the heart of everything we do
For over 60 years Novartis has been committed to helping people with cardiovascular disease and we remain steadfast in that commitment to this day.